Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis

Clin Rheumatol. 2007 Dec;26(12):2205-2206. doi: 10.1007/s10067-007-0733-8. Epub 2007 Sep 18.

Authors

K Vandevyvere¹, F P Luyten¹, P Verschueren¹, R Lories¹, S Segaert², R Westhovens³

Affiliations

¹ Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
² Division of Dermatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
³ Division of Rheumatology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. Rene.Westhovens@uz.kuleuven.be.

PMID: 17876646
DOI: 10.1007/s10067-007-0733-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antibodies, Monoclonal / therapeutic use
Antirheumatic Agents / adverse effects*
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy*
Female
Follow-Up Studies
Humans
Infliximab
Middle Aged
Pyoderma Gangrenosum / chemically induced*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Infliximab